Hoth Therapeutics Inc - HOTH STOCK NEWS

Hoth Therapeutics (NASDAQ: HOTH) has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received official notification from Nasdaq on January 23, 2025, confirming compliance after maintaining a closing bid price at or above $1.00 per share for 10 consecutive business days, from January 7 to January 22, 2025.

CEO Robb Knie emphasized this achievement as a reflection of the company's commitment to creating long-term shareholder value and maintaining high corporate governance standards. The biopharmaceutical company confirms its continued focus on advancing its pipeline and delivering healthcare solutions.

Hoth Therapeutics (NASDAQ: HOTH) has announced the acquisition and expansion of patent applications to strengthen its intellectual property portfolio. The new patents will be utilized to explore additional indications for the company's HT-001 Cancer Therapeutic.

The company positions these acquisitions as part of its strategy to develop innovative treatments for unmet medical needs, focusing on enhancing therapeutic efficacy and expanding applications across various disease areas. CEO Robb Knie emphasized that these provisional patent applications reinforce Hoth's proprietary approaches and align with their mission to deliver breakthrough therapies.

Hoth Therapeutics (NASDAQ: HOTH) has announced its participation in the upcoming Sequire Investor Summit, scheduled for January 21-23, 2025. The company's Chief Executive Officer, Robb Knie, will be attending the event, representing the biopharmaceutical company at this significant investor conference.

Hoth Therapeutics (NASDAQ: HOTH) has addressed market rumors and shareholder inquiries by confirming it has no plans for public or private offerings. The company highlighted its strong financial position with over $10 million in cash and no debt, emphasizing its ability to execute strategic initiatives without immediate need for additional financing.

The company also reported progress in its clinical development, announcing that all trial sites for HT-001, its lead therapeutic candidate for treating rash and skin disorders associated with cancer therapy, are now active and enrolling participants. CEO Robb Knie emphasized the company's focus on creating long-term value and advancing clinical programs, stating that the activation of all trial sites represents a significant milestone in HT-001's development.

Hoth Therapeutics (NASDAQ: HOTH) has announced promising interim results from its Phase 2a clinical trial of HT-001, a treatment targeting skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. The CLEER-001 trial demonstrated 100% success rate in achieving the primary efficacy endpoint, with all patients showing significant skin toxicity improvement within six weeks.

Key outcomes include 66% of patients reporting reduced pain and itching scores, and notably, all patients maintained their full EGFRi cancer treatment dosage without reductions. The trial utilizes the proprietary Acneiform Rash Investigator Global Assessment Scale (ARIGA) for precise measurement of improvements. Importantly, no treatment-related adverse effects were reported, confirming HT-001's safety profile.

Hoth Therapeutics (NASDAQ: HOTH) has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University for technology focused on 'Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.' The agreement grants Hoth exclusive rights to develop, market, and commercialize products from the licensed patents.

Additionally, Hoth has signed an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001, expanding its application to other cancer therapeutics. The company plans to advance the obesity-related technology from research through commercialization following a comprehensive development plan.

Hoth Therapeutics (NASDAQ: HOTH) announced its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company cites Bitcoin's growing investor acceptance, recent ETF approvals, and increased institutional investor activity as key factors in this decision. CEO Robb Knie emphasized Bitcoin's potential as an inflation-resistant store of value and its emergence as a major asset class.

Hoth Therapeutics (NASDAQ: HOTH) has reported promising early data from a preclinical study of its cancer treatment HT-KIT, conducted at NC State University. The preliminary results show that the treatment effectively stabilized tumor growth with remarkable consistency across subjects. Key findings include stabilized tumor volumes in treated subjects, high consistency across treated animals with minimal error bars, and notable differences compared to untreated controls which showed greater variability and increased tumor volume.

Hoth Therapeutics (NASDAQ: HOTH) has been granted a U.S. patent for its innovative Alzheimer's treatment, HT-ALZ. This breakthrough therapy targets the Substance P/Neurokinin-1 Receptor pathway, which is important in neuroinflammation, a key factor in Alzheimer's progression. Preclinical studies have shown promising results, including reduced neuroinflammation and improved cognitive functions.

The company is now preparing for human clinical trials, with formulation of HT-ALZ currently underway. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in addressing cognitive decline associated with Alzheimer's disease. This patent secures Hoth's intellectual property rights and strengthens its position in Alzheimer's therapy development.